It took close to three years, but Germany's Evotec AG has finally reached its first big milestone in a biomarker collaboration first signed with Switzerland drug and diagnostic giant Roche back in 2011.
Many drugs used to treat lung, breast and pancreatic cancers also promote drug resistance and can ultimately spur tumor growth. Now, researchers may be able to predict which individual tumors will metastasize and spread when treated with certain drugs.
KineMed, a California biomarker test developer with IPO plans, is joining a consortium that will create a standard mouse model focused on diagnosis and tracking of early-onset diabetes.
A rapid diagnostic blood test for asthma--one that works even in mild cases, before symptoms appear--showed some promise in new research. What's more, the handheld device developed for the diagnostic process would cost little to use, they said.
Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
A harmful gene mutation that increases a woman's risk of developing breast and ovarian cancer may also play a role in brain development, according to new findings by scientists at the Salk Institute for Biological Studies.
Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.
International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.
U.K. researchers have made advances developing a blood test that could screen for patients who have a genetic predisposition to obesity. Their work, published in the journal Diabetes, involves a team from the University of Southampton, University of Exeter Medical School and elsewhere.
A new diagnostic test screens for 5 protein biomarkers that can help differentiate septic shock patients at high or low risk for death. If further testing supports the initial findings, doctors will gain a tool to help them determine which patients need experimental therapies and which should get more traditional treatment.